Maze Therapeutics reports positive data from Phase I AKD treatment trial

Maze Therapeutics has revealed positive outcome from the Phase I clinical trial in healthy volunteers assessing oral MZE829, being developed to potentially treat apolipoprotein L1 (APOL1) kidney disease (AKD).